A Growing Pipeline

We are working on the discovery and early development of potential Adnectin therapeutics across a range of disease types.

Our research strategy is to create differentiated Adnectin-based compound candidates that meet areas of important unmet medical need. Working with our colleagues in the broader Bristol-Myers Squibb organization, we pursue the discovery and development of targets which meet the following criteria:

• high degree of confidence in the biological pathway intervention point
• potential for clinically meaningful differentiation versus existing treatments

Adnectins may be broadly applicable to a wide range of targets, creating an opportunity to study potentially differentiated compounds across many therapeutic areas.